Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dr Dozo Laboratories is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area, where it has 1 pending office action. This single action represents the current active engagement with the patent office for the company. The prosecution is concentrated, as the data shows 1 distinct examiner and 1 distinct art unit are involved in the review of the intellectual property. This suggests a specific and narrow focus for the current legal proceedings.
The examiner assigned to this matter is FIEBIG, RUSSELL G, who is designated as the busiest examiner for the portfolio. FIEBIG, RUSSELL G is responsible for 1 busiest examiner pending office action. Because there is 1 distinct examiner and 1 distinct art unit, the immediate prosecution strategy is dependent on the interactions within this single administrative channel. This lack of distribution across multiple examiners or art units simplifies the management of the portfolio but increases the impact of the individual examiner's decisions.
With 1 pending office action being handled by the assigned staff, the company faces a streamlined path toward patent allowance. The involvement of the Biotechnology & Pharmaceuticals technology area confirms that the subject matter remains within a specific technical niche. Practitioners should focus on the specific requirements of the busiest examiner, as this individual holds the 1 busiest examiner pending action. The relationship between the 1 distinct examiner and the pending action highlights the focused nature of this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038418 | A PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038418 | A PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038418 | A PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION | FIEBIG, RUSSELL G | 1600 | §103§112 | Non-Final OA | — | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial